Discontinued ADD drug too risky: FDA
Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.
“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.
In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on January 16, 2017, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/